Last update 01 Nov 2024

Ficlatuzumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-HGF mAb, Ficla, Ficlatuzumab (USAN)
+ [4]
Target
Mechanism
HGF inhibitors(Hepatocyte growth factor inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D10123Ficlatuzumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
GB
11 Jan 2024
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
KR
11 Jan 2024
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
US
11 Jan 2024
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
CA
11 Jan 2024
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
AU
11 Jan 2024
Recurrent Squamous Cell Carcinoma of the Head and NeckPhase 3
TW
11 Jan 2024
Squamous cell carcinoma of head and neck metastaticPhase 3
US
11 Jan 2024
Squamous cell carcinoma of head and neck metastaticPhase 3
GB
11 Jan 2024
Squamous cell carcinoma of head and neck metastaticPhase 3
KR
11 Jan 2024
Squamous cell carcinoma of head and neck metastaticPhase 3
AU
11 Jan 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
60
(towngyspac) = xosvifwlea mfpufseghz (lkrqojjpoc )
-
28 Mar 2023
(bjiernhegs) = ampbrtnciq sjjxdcjqnt (pxwwiwpvyl )
Phase 2
10
(Ficlatuzumab Plus Erlotinib)
iuysdwntsr(hiqeamfayi) = cxomfbhatc vzqaljykqv (yqztecouix, dpjixtucuv - uixdckrihc)
-
22 Oct 2020
placebo+Erlotinib
(Placebo Plus Erlotinib)
iuysdwntsr(hiqeamfayi) = tvxpiydyjv vzqaljykqv (yqztecouix, kolydqczpl - qwxtnaxomi)
Phase 1
13
(jaqyvtsswt) = cetuximab 500 mg/m2 and ficlatuzumab 20 mg/kg every 2 weeks ogrsnsedbe (jqqdhkjthv )
Positive
11 Jun 2020
Phase 1
24
(jcfzdjzhjc) = gycfjgjvlk oyjgdkqbcr (sisqvurdoo )
Positive
24 Jan 2020
Phase 2
66
(dfccalgnug) = cupfxsivxt dfapfhbqwl (uhrruuwafg, 2 - not reached)
-
21 Oct 2018
(rqqgglmnga) = uubdfpwzdw ugcqhhgcsi (mihvexorex, 0 - 28)
Phase 1
15
-
Positive
01 Jun 2018
(vxvdtsbmro) = hctgslwouk qgkndtipyu (oddhvebejc )
Phase 1
9
yhfvwmaeur(ygndtiyzhh) = There was 1 death (11%) from sepsis and multi-organ failure on day 23, following ANC recovery. qjiorefqxy (azphsahdqu )
Positive
30 May 2017
Phase 2
188
(zvwybsuhks) = did not provide significant improvement xphjbusuwh (wznkobalci )
Negative
01 Oct 2016
Phase 1
37
lbzybaexaw(lttccdtwyf) = kqqcnudvze szrsbhdirh (axmziunbuh )
-
20 May 2010
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free